Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $43.01, for a total transaction of $498,098.81. Following the sale, the chief financial officer now directly owns 107,789 shares of the company’s stock, valued at approximately $4,636,004.89. The trade was a 9.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $38.92, for a total transaction of $450,732.52.
• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Stock Performance

HIMS stock opened at $46.43 on Thursday. Hims & Hers Health, Inc. has a one year low of $9.14 and a one year high of $46.50. The firm’s fifty day moving average is $30.98 and its 200 day moving average is $23.74. The firm has a market cap of $10.14 billion, a PE ratio of 105.53 and a beta of 1.35.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HIMS shares. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Needham & Company LLC upped their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Finally, Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.